{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:15:26Z","timestamp":1788426926620,"version":"build-2803163510"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bernard Pollack Professor"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32GM145408"],"award-info":[{"award-number":["T32GM145408"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mayo Clinic Medical Scientist Training Program","award":["F30CA294722-01"],"award-info":[{"award-number":["F30CA294722-01"]}]},{"name":"Mayo Clinic Medical Scientist Training Program","award":["K99NS138490"],"award-info":[{"award-number":["K99NS138490"]}]},{"name":"Mayo Clinic Medical Scientist Training Program","award":["R35GM143949"],"award-info":[{"award-number":["R35GM143949"]}]},{"name":"Mayo Clinic Medical Scientist Training Program","award":["R61NS128071-01A1"],"award-info":[{"award-number":["R61NS128071-01A1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) is an aggressive, high-grade glioma with a near-universally fatal prognosis. Therapeutic failure is often attributed to the highly selective blood-brain barrier (BBB), the diffuse infiltrative nature of the tumor, and the marked intratumoral heterogeneity of GBM. Although antibody-drug conjugates (ADCs) have shown promise for high-grade gliomas such as GBM, efficacy is limited by ADC size. Aptamers\u2014short, synthetic, single-stranded DNA or RNA molecules\u2014can be \u223c6-fold lower in molecular weight than IgG antibodies and have the potential to cross the intact BBB. Unlike other nucleic acid-based therapies, aptamer function arises from three-dimensional shape rather than genetic coding. Here we aim to replace the targeting component of the ADC paradigm with a DNA aptamer, thus creating an aptamer-drug conjugate (ApDC). We employed in vivo SELEX using an orthotopic patient-derived xenograft GBM mouse model and a vast (\u223c100 trillion 80-mer sequences) ApDC library. We report the results from this first\u00a0in vivo ApDC selection of its kind. We characterize target tissue binding ex vivo, cell association, biodistribution, and pharmacokinetics from this selection. This study exemplifies an unbiased approach to a problem that rational design has yet to overcome, offering a new direction for GBM therapeutic development.<\/jats:p>","DOI":"10.1093\/narcan\/zcag022","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:47:21Z","timestamp":1787226441000},"source":"Crossref","is-referenced-by-count":0,"title":["<i>In vivo<\/i>\n                    selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft model"],"prefix":"10.1093","volume":"8","author":[{"given":"Caroline D","family":"Doherty","sequence":"first","affiliation":[{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Graduate School of Biomedical Sciences , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren L","family":"Ott","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie K","family":"Bakken","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1583-023X","authenticated-orcid":false,"given":"Brandon A","family":"Wilbanks","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Mayo Clinic Graduate School of Biomedical Sciences , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M","family":"Burgenske","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keenan S","family":"Pearson","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Mayo Clinic Graduate School of Biomedical Sciences , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica I","family":"Griffith","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, University of Minnesota, Minneapolis,MN 55455,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichen","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Meridew","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saigopalakrishna S","family":"Yerneni","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F","family":"Elmquist","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, University of Minnesota, Minneapolis,MN 55455,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7489-4885","authenticated-orcid":false,"given":"Jann N","family":"Sarkaria","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Mayo Clinic Graduate School of Biomedical Sciences , Rochester, MN 55905 ,","place":["United States"]},{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5043-6422","authenticated-orcid":false,"given":"Louis J","family":"Maher,\u00a0III","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Mayo Clinic Graduate School of Biomedical Sciences , Rochester, MN 55905 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2026090304335522000_B1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody\u2013drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol Cancer"},{"key":"2026090304335522000_B2","doi-asserted-by":"publisher","first-page":"2614669","DOI":"10.1080\/19420862.2026.2614669","article-title":"Antibodies to watch in 2026","volume":"18","author":"Crescioli","year":"2026","journal-title":"MAbs"},{"key":"2026090304335522000_B3","first-page":"362","article-title":"Advancements in antibody-drug conjugates as cancer therapeutics","volume":"5","author":"Fong","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"2026090304335522000_B4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMp048021","article-title":"Paul Ehrlich\u2019s magic bullets","volume":"350","author":"Schwartz","year":"2004","journal-title":"N Engl J Med"},{"key":"2026090304335522000_B5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nrclinonc.2017.95","article-title":"Antibody\u2013drug conjugates in glioblastoma therapy: the right drugs to the right cells","volume":"14","author":"Gan","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2026090304335522000_B6","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1093\/neuonc\/noab133","article-title":"Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody-drug conjugate in glioblastoma","volume":"23","author":"Marin","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026090304335522000_B7","doi-asserted-by":"publisher","first-page":"vi17","DOI":"10.1093\/neuonc\/noz175.065","article-title":"Actr-22. initial treatment of gbm with a ketogenic diet along with radiation and chemotherapy: clinical outcomes","volume":"21","author":"Schwartz","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026090304335522000_B8","doi-asserted-by":"publisher","first-page":"718590","DOI":"10.3389\/fonc.2021.718590","article-title":"Antibody-drug conjugates in glioblastoma\u2014is there a future for them?","volume":"11","author":"Parakh","year":"2021","journal-title":"Front Oncol"},{"key":"2026090304335522000_B9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11060-020-03451-6","article-title":"Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis","volume":"147","author":"Marenco-Hillembrand","year":"2020","journal-title":"J Neurooncol"},{"key":"2026090304335522000_B10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/neuonc\/noad156","article-title":"Aptamers in neuro-oncology: an emerging therapeutic modality","volume":"26","author":"Doherty","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026090304335522000_B11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ddtec.2016.07.009","article-title":"Exploiting transferrin receptor for delivering drugs across the blood-brain barrier","volume":"20","author":"Paterson","year":"2016","journal-title":"Drug Discov Today Technol"},{"key":"2026090304335522000_B12","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.1021\/acs.molpharmaceut.5c01417","article-title":"Drug delivery strategies to cross, target, or bypass the blood\u2013brain barrier","volume":"22","author":"Kandimalla","year":"2025","journal-title":"Mol Pharmaceutics"},{"key":"2026090304335522000_B13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/neuonc\/noac173","article-title":"Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial","volume":"25","author":"Lassman","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026090304335522000_B14","doi-asserted-by":"crossref","first-page":"664236","DOI":"10.3389\/fonc.2021.664236","article-title":"High-affinity chimeric antigen receptor with cross-reactive scFv to clinically relevant EGFR oncogenic isoforms","volume":"11","author":"Thokala","year":"2021","journal-title":"Front Oncol"},{"key":"2026090304335522000_B15","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/cancers15051414","article-title":"CAR T cell therapy in glioblastoma: overcoming challenges related to antigen expression","volume":"15","author":"Luksik","year":"2023","journal-title":"Cancers"},{"key":"2026090304335522000_B16","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1126\/science.287.5454.820","article-title":"Adaptive recognition by nucleic acid aptamers","volume":"287","author":"Hermann","year":"2000","journal-title":"Science"},{"key":"2026090304335522000_B17","doi-asserted-by":"publisher","first-page":"e70245","DOI":"10.1111\/acel.70245","article-title":"An unbiased cell-culture selection yields dna aptamers as novel senescent cell-specific reagents","volume":"24","author":"Pearson","year":"2025","journal-title":"Aging Cell"},{"key":"2026090304335522000_B18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/15476286.2017.1414131","article-title":"Aptamers in HIV research diagnosis and therapy","volume":"15","author":"Bala","year":"2018","journal-title":"RNA Biol"},{"key":"2026090304335522000_B19","doi-asserted-by":"publisher","first-page":"zcaf005","DOI":"10.1093\/narcan\/zcaf005","article-title":"In vivo selection of anti-glioblastoma DNA aptamers in an orthotopic patient-derived xenograft model","volume":"7","author":"Doherty","year":"2025","journal-title":"NAR Cancer"},{"key":"2026090304335522000_B20","doi-asserted-by":"publisher","first-page":"16.1","DOI":"10.1002\/0471141755.ph1416s52","article-title":"Establishment, maintenance, and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery","volume":"52","author":"Carlson","year":"2011","journal-title":"Curr Protoc Pharmacol"},{"key":"2026090304335522000_B21","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/1078-0432.CCR-19-0909","article-title":"Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma","volume":"26","author":"Vaubel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026090304335522000_B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-76572-7","article-title":"MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression","author":"Hofst\u00e4tter\u00a0Azambuja","year":"2026","journal-title":"Nat Commun"},{"key":"2026090304335522000_B23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s43018-022-00348-3","article-title":"Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome","volume":"3","author":"Golbourn","year":"2022","journal-title":"Nat Cancer"},{"key":"2026090304335522000_B24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.omtn.2022.08.030","article-title":"FASTAptameR 2.0: a web tool for combinatorial sequence selections","volume":"29","author":"Kramer","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026090304335522000_B25","doi-asserted-by":"publisher","first-page":"114712","DOI":"10.1016\/j.ab.2022.114712","article-title":"Optimized quantitative PCR analysis of random DNA aptamer libraries","volume":"650","author":"Pearson","year":"2022","journal-title":"Anal Biochem"},{"key":"2026090304335522000_B26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.omtn.2018.04.006","article-title":"AptaSUITE: a full-featured bioinformatics framework for the comprehensive analysis of aptamers from HT-SELEX experiments","volume":"11","author":"Hoinka","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026090304335522000_B27","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-24-0426","article-title":"Bystander effects, pharmacokinetics, and linker-payload stability of EGFR-targeting antibody-drug conjugates losatuxizumab vedotin and depatux-M in glioblastoma models","volume":"30","author":"Jain","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026090304335522000_B28","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3390\/jcm10061332","article-title":"Whole-body pharmacokinetics and physiologically based pharmacokinetic model for monomethyl auristatin E (MMAE)","volume":"10","author":"Chang","year":"2021","journal-title":"J Clin Med"},{"key":"2026090304335522000_B29","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/nar\/gkg595","article-title":"Mfold web server for nucleic acid folding and hybridization prediction","volume":"31","author":"Zuker","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2026090304335522000_B30","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1038\/s41598-019-41460-2","article-title":"Targeting hormone refractory prostate cancer by in vivo selected DNA libraries in an orthotopic xenograft mouse model","volume":"9","author":"Civit","year":"2019","journal-title":"Sci Rep"},{"key":"2026090304335522000_B31","doi-asserted-by":"publisher","first-page":"100849","DOI":"10.1016\/j.medj.2025.100849","article-title":"Antibody-drug conjugates: current challenges and innovative solutions for precision cancer therapy","volume":"6","author":"Zhou","year":"2025","journal-title":"Med"},{"key":"2026090304335522000_B32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2026090304335522000_B33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/1074-5521(95)90032-2","article-title":"Nuclease-resistant nucleic acid ligands to vascular permeability factor\/vascular endothelial growth factor","volume":"2","author":"Green","year":"1995","journal-title":"Chem Biol"},{"key":"2026090304335522000_B34","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1038\/mtna.2016.81","article-title":"Conjugate-SELEX: a high-throughput screening of thioaptamer-liposomal nanoparticle conjugates for targeted intracellular delivery of anticancer drugs","volume":"5","author":"Mu","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026090304335522000_B35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1021\/ja311331m","article-title":"DNA ligase-mediated translation of DNA into densely functionalized nucleic acid polymers","volume":"135","author":"Hili","year":"2013","journal-title":"J Am Chem Soc"},{"key":"2026090304335522000_B36","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41557-018-0008-9","article-title":"Evolution of sequence-defined highly functionalized nucleic acid polymers","volume":"10","author":"Chen","year":"2018","journal-title":"Nature Chem"},{"key":"2026090304335522000_B37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41589-019-0229-2","article-title":"Side chain determinants of biopolymer function during selection and replication","volume":"15","author":"Lichtor","year":"2019","journal-title":"Nat Chem Biol"},{"key":"2026090304335522000_B38","doi-asserted-by":"publisher","first-page":"9237","DOI":"10.1073\/pnas.161293498","article-title":"Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition","volume":"98","author":"Bauer","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026090304335522000_B39","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","article-title":"DNA sensing by the cGAS\u2013STING pathway in health and disease","volume":"20","author":"Motwani","year":"2019","journal-title":"Nat Rev Genet"},{"key":"2026090304335522000_B40","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1038\/s41467-018-04982-3","article-title":"Glutamic acid\u2013valine\u2013citrulline linkers ensure stability and efficacy of antibody\u2013drug conjugates in mice","volume":"9","author":"Anami","year":"2018","journal-title":"Nat Commun"},{"key":"2026090304335522000_B41","doi-asserted-by":"publisher","first-page":"pgad151","DOI":"10.1093\/pnasnexus\/pgad151","article-title":"Peroxidase proximity selection to identify aptamers targeting a subcellular location","volume":"2","author":"Wilbanks","year":"2023","journal-title":"PNAS Nexus"},{"key":"2026090304335522000_B42","doi-asserted-by":"publisher","first-page":"110839","DOI":"10.1016\/j.celrep.2022.110839","article-title":"Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors","volume":"39","author":"Anami","year":"2022","journal-title":"Cell Rep"},{"key":"2026090304335522000_B43","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1111\/bcp.16057","article-title":"Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E-based antibody\u2013drug conjugates","volume":"90","author":"Chang","year":"2024","journal-title":"Brit J Clinical Pharma"}],"container-title":["NAR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/narcancer\/article-pdf\/8\/3\/zcag022\/70935362\/zcag022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/narcancer\/article-pdf\/8\/3\/zcag022\/70935362\/zcag022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:34:02Z","timestamp":1788424442000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/narcancer\/article\/doi\/10.1093\/narcan\/zcag022\/8780938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,27]]}},"URL":"https:\/\/doi.org\/10.1093\/narcan\/zcag022","relation":{},"ISSN":["2632-8674"],"issn-type":[{"value":"2632-8674","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,27]]},"article-number":"zcag022"}}